TruSight Oncology 500 High-Throughput
FFPEサンプルから、一回192サンプルまで解析できるゲノムプロファイリングアッセイです。Read More...
Library Prep
Software Options
Index Adapters
Reagents
Services
合計：
TruSight Oncology 500 High-ThroughputアッセイはTruSight Oncology 500アッセイをベースに、サンプルスループットとバッチオプションを向上させる柔軟性を備えています。
複数のバイオマーカーを一つのアッセイに統合
合理化されたサンプルからバリアントコールレポートまでのワークフロー
高いサンプルスループット
高い信頼性の結果を達成
施設内での包括的ゲノムプロファイリングの実現
このファミリーに含まれる3つのアッセイはすべて、主要ガイドラインや臨床試験に含まれる重要なバイオマーカーを検出するように設計されています。
FFPE検体から関連がんバイオマーカーを解析できます
TruSight Oncology 500アッセイ同様、組織検体から同じバイオマーカーを検出し、一回192サンプルまで解析できます
血漿検体から血中ctDNAを対象に、TruSight Oncology 500アッセイのDNAパネルと同じ遺伝子を解析します
| TruSight Oncology 500 High-Throughput | TruSight Oncology 500 | TruSight Oncology 500 ctDNA | |
|---|---|---|---|
| Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer |
| Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55
genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. |
Targeted selection of DNA from 523 genes of interest, and RNA from 55
genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. |
Targeted selection of 523 genes (full coding sequence) for a total of
1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Immuno-oncology Biomarker Coverage: TMB and MSI* |
| Hands-On Time | ~10.5 hours | ~10.5 hours | ~10.5 hours |
| Input Quantity | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 40 ng DNA, 40 ng RNA | 30 ng cfDNA (8-10 ml of plasma) |
| Method | Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing | Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing | Target Enrichment , Target Enrichment, Targeted DNA Sequencing |
| Nucleic Acid Type | DNA, RNA | DNA, RNA | DNA |
| Sample Throughput | 16–192 samples per flow cell | ||
| Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Cell-Free DNA |
| Species Category | Human | Human | Human |
| System Compatibility | NovaSeq 6000 | NextSeq 500 , NextSeq 550 , NextSeq 550Dx in Research Mode | NovaSeq 6000 |
| Technology | Sequencing | Sequencing | Sequencing |
| Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Somatic Variants |
High concordance of TMB analysis between TruSight Oncology 500 and TruSight Oncology 500 High Throughput.
High concordance of MSI analysis between TruSightOncology 500 and TruSight Oncology 500 High Throughput.
High concordance of VAF between TruSightOncology 500 and TruSight Oncology 500 High Throughput.
Fusion and splice variants as detected using TruSight Oncology 500 o the NextSeq 500 System. Numeric values represent the number of supporting reads for each sample at the indicated RNA input amount. Cut-off value for RNA fusions = 5; cut-off value for splice variants = 10.
Content for TruSight Oncology 500 and TruSight Oncology 500 High-Throughput includes key guideline biomarkers for multiple cancer types, plus current and emerging pan-cancer biomarkers such as TMB, MSI, NTRK1, NTRK2, and NTRK3.
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF< 1 MB
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF3 MB
Data Sheet | PDF | 4 versions
TruSight Oncology 500 High Throughput Consumables & Equipment Documentation
TruSight Oncology 500 High Throughput Checklist Documentation
TruSight Oncology 500 High Throughput Reference Guide Documentation
カスタムプロトコルセレクタ
Generates customized, end-to-end instructions
マイクロサテライト不安定性（MSI） やTumor Mutational Burden（TMB）を含む、血漿サンプルから複数の体細胞バリアントタイプをターゲットとするアッセイです。
Tumor mutational burden (TMB)、マイクロサテライト不安定性（MSI）などを含むさまざまなバリアントタイプをターゲットとしたアッセイです。
* Based on PierianDx Clinical knowledgebase, as of March 2020
